Rapport Therapeutics, Inc. RAPP Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s additional paid-in capital?
- Rapport Therapeutics, Inc. (RAPP) reported additional paid-in capital of $727.05M in Q1 2026.
- How has Rapport Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Rapport Therapeutics, Inc.'s additional paid-in capital increased by 67.6% year-over-year, from $433.7M to $727.05M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s additional paid-in capital has grown at a 502.8% compound annual growth rate (CAGR), from $19.8M to $719.29M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.